A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial. The results of the randomized, double-blind, placebo-controlled trial of infliximab were published in the first issue of the May American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.>>> Discuss This Story
